Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fisher, R. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fisher, R. I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 7:S35-S39, 1996
© 1996 European Society for Medical Oncology

Reviews

Mantle-cell lymphoma: Classification and therapeutic implications

R. I. Fisher

Division of Hematology/Oncology, Loyola University Cancer Center Maywood, IL, USA

Correspondence to: Richard I. Fisher, MD Division of Hematology/Oncology Loyola University Cancer Center 2160 S First Avenue Maywood, IL 60153-5500 USA

Mantle-cell lymphomas have been recognized in the new Revised European-American Lymphoma Classification as a peripheral B-cell neoplasm that has a distinct morphologic, immunologic, and genetic phenotype. Mantle-cell lymphomas have been subtyped into four categories, termed ‘mantle zone’, ‘nodular’, ‘diffuse’, or ‘blastoid’. The incidence of the ‘mantle-zone’ pattern remains controversial. The fact that patients with the nodular, diffuse, or blastoid subtypes of mantle-cell lymphoma have a high proliferative rate resulting from overexpression of the cyclin D1 and a very short median survival demonstrates conclusively that these patients should be categorized as having an aggressive lymphoma. Most authorities believe that the ‘mantle zone’ variant pursues a more benign clinical course than the other subtypes. Trials of the new purine analogs are of great interest in these mantle-zone lymphoma patients.

B-cell lymphoma, classification systems, MCL, purine analogs, REAL classification, Working Formulation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.